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Abstract
Phosphatidic acid (PA) is an important signaling lipid that plays roles in a range of biological 
processes including both physiological and pathophysiological events. PA is one of a number of 
signaling lipids that can act as site-specific ligands for protein receptors in binding events that 
enforce membrane-association and generally regulate both receptor function and subcellular 
localization. However, elucidation of the full scope of PA activities has proven problematic, 
primarily due to the lack of a consensus sequence among PA-binding receptors. Thus, 
experimental approaches, such as those employing lipid probes, are necessary for characterizing 
interactions at the molecular level. Herein, we describe an efficient modular approach to the 
synthesis of a range of PA probes that employs a late stage introduction of reporter groups. This 
strategy was exploited in the synthesis of PA probes bearing fluorescent and photoaffinity tags as 
well as a bifunctional probe containing both a photoaffinity moiety and an azide as a secondary 
handle for purification purposes. To discern the ability of these PA analogues to mimic the natural 
lipid in protein binding properties, each compound was incorporated into vesicles for binding 
studies using a known PA receptor, the C2 domain of PKCα. In these studies, each compound 
exhibited binding properties that were comparable to those of synthetic PA, indicating their 
viability as probes for effectively studying the activities of PA in cellular processes.
Introduction
Binding interactions in which receptors, termed peripheral proteins, interact with the 
surfaces of cellular membranes are known to control a litany of crucial physiological and 
pathophysiological processes. While a number of mechanisms for membrane targeting of 
cytosolic proteins exist, a common motif involves the actions of lipids such as phosphatidic 
acid (PA),1–3 diacylglycerol (DAG),4,5 and the phosphoinositides (PIPns)6–11 as site-specific 
ligands that enforce the membrane-anchoring of protein receptors. The presence of signaling 
lipids in cellular membranes is tightly regulated both spatially and temporally, and thus their 
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presentation directly controls the localization of receptors within the cell.12 In addition, the 
binding of peripheral proteins to the membrane generally regulates the function of the 
receptor. Protein function can either be directly affected by lipid binding or indirectly 
regulated, such as through interaction with another protein that is localized to the membrane 
surface.4,5,13,14 It is now apparent that protein–lipid binding events are particularly 
prominent in regulating crucial processes, and thus defects in binding and lipid composition 
result in serious diseases. For example, despite the relative simplicity of its structure, PA 
plays a vital role in carcinogenesis by regulating the function of Raf-1 kinase through 
binding, a protein that is involved in vital cellular pathways.15,16 As a result of these 
implications, it is important to elucidate the complex details pertaining to protein–lipid 
binding interactions.
To date, a number of receptors that target PA2,3 have been identified, including protein 
kinases,17–19 protein phosphatases,20–22 and cAMP-specific phosphodiesterases.23,24 A 
particularly well studied example is Raf-1 kinase, an enzyme that interacts with cellular 
membranes by binding both PA and phosphatidylserine (PS) using separate binding 
domains.25 When bound to the membrane surface, Raf-1 forms a protein–protein interaction 
with membrane-associated Ras GTPases, which activates Raf-1 to initiate the 
Ras/Raf/MEK/ERK cell proliferation pathway that is aberrant in cancer.25–32 Other 
receptors that interact with PA include certain isoforms of the protein kinase C (PKC) 
family, such as PKCα33 and PKCε,34 which are heavily involved in cancer onset. This 
family consists of at least eleven isozymes that exhibit varying lipid-binding properties, 
opposing or overlapping functions, and differing localization profiles, complicating their 
study.4,5,35–38 Each PKC contains two C1 domains that interact with DAG as well as a C2 
domain that often binds to a phospholipid target that varies among the different isoforms, 
including PA and PS. The exact roles of the different PKCs in carcinogenesis remain 
unknown due to challenges in characterizing variations in activity that occur among the 
isozymes.39–41 A current hypothesis is that subtle differences in lipid-binding patterns 
between the PKC isozymes result in discrepancies in their subcellular localization that in 
turn regulate function.5,42
One focus of research seeks to understand how receptors could possess specificity in the 
binding of PA over other lipids bearing negative charge that are often significantly more 
abundant. Problems related to this issue often lead to the misidentification of PA receptors.
2,43
 de Kruijff and coworkers have presented an electrostatic hydrogen bond switch 
mechanism to explain the specificity of PA as a ligand despite its simple structure.43,44 Their 
results showed that monoprotonated PA is stabilized by an intramolecular hydrogen bond 
that preserves the -1 charge, causing proteins and peptides with basic residues to associate to 
the membrane via electrostatic attraction. Following this initial interaction, hydrogen bonds 
are formed between the receptor and PA headgroup that immediately lead to full phosphate 
deprotonation (-2 charge). This charge increase enhances association and provides binding 
specificity. The shape of PA is also believed to contribute to binding specificity.43 At 
physiological pH, PA exists as a cone-shaped structure, which causes the phosphate 
headgroup to lie below the membrane surface in the mildly polar interfacial region.45 This 
presentation is thought to enhance the penetration of hydrophobic residues into the 
membrane around the PA binding domain. The presentation of PA in the membrane and the 
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charge-reinforced H-bonding enforced during binding are depicted in Figure 1A. Both of 
these concepts are observed in the binding of PA by Raf-1 kinase,25,27,43 and PKCs,33,34 
which contain basic amino acids that are crucial for PA recognition as well as hydrophobic 
residues that penetrate the membrane during binding.
Despite these advancements in understanding the actions of PA as a ligand, the full scope of 
PA-targeting proteins is not yet clear as the number of identified receptors is relatively small 
compared to the biological processes that show PA-dependence. A primary complication in 
the discovery of PA-binding proteins is that these receptors generally don’t possess 
conserved consensus sequences that can be employed for sequence homology searching.2,3,8 
The PA binding domains established to date are diverse and consist of sequences that were 
not previously known to bind lipids.2 In fact, the only common link that many of the PA 
binding domains share are small clusters of basic (Arg, Lys, Trp) amino acids.2,3,8,43 Due to 
this inability to discover PA-binding receptors via structure searches, experimental 
approaches are crucial for elucidating binding interactions. As such, chemical probes are 
vital for studying and characterizing protein–PA binding interactions at the molecular level.
Results and Discussion
Synthetic PA probes have previously proven effective for probing receptors that target this 
lipid. For example, Nemoz and coworkers developed a photoaffinity-tagged PA probe that 
was used in the covalent labeling of type 4 cAMP-phosphodiesterases (PDE4).46 The 
photoaffinity label was incorporated into the acyl tails of commercial lipids, which is 
effective for proteins that interact significantly with lipid chains buried within the 
hydrophobic membrane core. Ktistakis and coworkers have designed a fully synthetic PA 
probe that was attached to beads via an amine incorporated into the sn-1 acyl tail.47,48 The 
resulting PA-functionalized resin was employed for affinity chromatography to selectively 
purify receptors that target this lipid. In addition, Prestwich and coworkers have developed 
synthetic fluoromethylene phosphonate analogs of PA as stabilized derivatives that are 
capable of activating the mTOR pathway.49 Gadella and coworkers developed a caged PA 
analog that was used to induced flagellar excision in algae.50 The introduction of an NPE 
caging moiety onto commercial lipids allowed the probe to cross the membrane, and 
photolysis produced an increase of PA within the cell that decreased the swimming of the 
algae. Finally, Schultz and coworkers have recently employed a bifunctional PA probe with a 
hydrolysable phosphate protecting group to achieve in vivo labeling of PA via bioorthogonal 
copper-free click chemistry.51
While these studies have proven lipid probes to be effective for characterizing biological 
activities, much remains to be learned about the roles of PA in cellular processes, and thus 
further probe strategies are necessary. The synthesis of lipid probes from scratch is 
beneficial as this increases cost efficiency, facilitates purification of the final probes, and 
allows for the exploration of a range of different modification strategies. For example, 
introduction of reporter groups in place of a hydrogen at the sn-1 headgroup position, which 
has rarely been pursued,52 is expected be effective for placing the added group proximal to a 
bound protein but away from the phosphate headgroup, the primary recognition moiety. 
However, a significant impediment to achieving broadly applicable probe strategies is the 
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synthesis required to produce each reporter-functionalized probe. Therefore, the optimal 
probe development approach would provide modularity such that a diverse array of reporter 
groups could be conveniently introduced at a late stage in the synthesis to access numerous 
probe structures.
Recently, we reported a modular approach to lipid probe synthesis that was employed for the 
synthesis of a range of DAG probes that each possess a reporter tag in place of a hydrogen at 
the headgroup sn-1 position.53 Functionalized probes were obtained from a core DAG 
scaffold bearing an azidomethyl group at the sn-1 position (1a, Figure 2) via the 
bioorthoganol azide-alkyne cycloaddition (click chemistry) reaction.54–56 Similar strategies 
have recently proven effective for facile derivatization of lipid scaffolds for bolaamphiphile 
development,57 and delivery and imaging58 applications. Despite modification of the 
headgroup position of DAG, the resulting probes exhibited Kd values in the binding of 
PKCδ that were virtually identical to natural DAG, indicating that this is a viable 
derivatization strategy.
Herein, we describe the extension of this probe strategy for the development of biologically 
active PA probes. Our design for a modular PA scaffold (1b) builds upon the success of the 
previous DAG analogue (1a). Initially, we attempted to synthesize 1b by simply installing 
the phosphate headgroup onto DAG scaffold 1a. However, as was the case during a number 
of attempts at the synthesis of 1a,53 we found that the use of phosphoramidite chemistry for 
this purpose led to a significant amount of sn-2 to sn-3 acyl migration, and thus this 
approach was not viable. In order to avoid the problems associated with acyl migration in 
hydroxyl-containing glycerol intermediates, our focus shifted to the development of a route 
in which the phosphate headgroup and azide tag are introduced early in the synthesis, prior 
to installation of the lipid acyl chains.
The current approach to the efficient development of numerous derivatized PA probes 
exploits protected azide-derivatized PA precursor 2 as a modular scaffold. The final 
synthetic route to this compound is indicated in Scheme 1. Protected tartrate analogue 5 was 
obtained from commercial diethyl-L-tartrate (3) using modified literature procedures for 
cyclopentylidene introduction to 4 and subsequent ester reduction. Next, mono-tosylation of 
bis-hydroxymethyl compound 5 was followed by azide substitution to furnish 6. The 
phosphate headgroup, protected as a phosphotriester, was then installed using dibenzyl 
diisopropylphosphoramidite (7) to afford 8. Careful removal of the cyclopentylidene acetal 
under acidic conditions was then employed to access diol 9. Finally, the acyl chains were 
introduced using traditional coupling reagents for esterification to obtain dibenzyl-protected 
azido-PA derivative 2. A key aspect of this synthesis was the determination of the optimal 
protecting group for the interior diol that could be removed to afford 9 without affecting the 
phosphotriester and azide groups. While several protecting group strategies were explored 
(see Supporting Information for details), the cyclopentylidene group of 7 proved most 
effective.
Following the synthesis of phosphotriester-protected PA analogue 2, we employed this 
scaffold for the efficient production of a number of derivatized PA probes (Scheme 2). The 
optimal approach involved initial reporter group introduction using click chemistry to couple 
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scaffold 2 to a range of functionalized alkynes (10a–e)53 in the generation of 
phosphotriesters 11a-e. The phosphotriester groups were subsequently deprotected with 
bromotrimethylsilane to generate PA probes 12a-e. This strategy was exploited to obtain PA 
probes derivatized with a range of fluorescent dyes (naphthyl (12a), dansyl (12b), coumarin 
(12c), and rhodamine (12d)) as well as with a photoaffinity tag (benzophenone (12e). 
Among the fluorescent analogues are different Förster resonance energy transfer (FRET) 
pairs, which are useful for detecting changes in proximity of donor and accepter-tagged 
molecules.59–63 Installation of the photoaffinity tag is advantageous for photo-cross-linking 
studies64 to characterize binding and map the location of binding domains on protein 
receptors.
In addition to probes 12a–e, we also sought to produce a bifunctional PA analogue that 
could be employed to purify, identify, and characterize PA-binding receptors. A significant 
challenge that has hindered elucidation of the full scope of PA activities is the difficulty 
associated with identifying PA-binding receptors, primarily due to the lack of a consensus 
sequence. Our strategy for probe development is inspired by the concept of activity-based 
protein profiling (ABPP), which uses substrate analogues as probes for a mechanism-based 
approach to the collective labeling of enzyme targets based on their activity.65–67 In the 
current approach, a PA probe (12f, Scheme 3) bearing both a photo-cross-linking group 
(benzophenone) for attachment to cognate receptors, as well as a secondary tag (azide) for 
purification of successfully cross-linked proteins is designed to fish out PA-binding 
receptors from a complex sample. Similar bifunctional designs have previously proven 
effective for this purpose,68,69 including a recent study that utilized a PC probe to identify 
receptors that target this lipid.70
The design of probe 12f employs a lysine moiety as a Y-shaped linker to introduce both the 
photo-cross-linking and azide groups onto PA. Thus, the synthesis of probe 12f commenced 
with fully protected lysine 13. First, hydrogenolysis was used to remove the carbobenzyloxy 
(cbz) group, followed by coupling to 4-benzoylbenzoic acid to introduce the benzophenone 
moiety of 14. Methyl ester hydrolysis was then performed prior to coupling with 
propargylamine in the generation of alkyne 10f. Next, the tert-butoxycarbonyl (boc) group of 
10f was removed, followed by the use of click chemistry to introduce PA scaffold 2, and 
finally coupling of the newly deprotected amine with 6-azidohexanoic acid71 to produce 
phosphotriester-protected PA analogue 11f. This was then deprotected with 
bromotrimethylsilane as before to access bifunctional probe 12f.
With these seven new derivatized PA probes (12a–f) that resulted from our modular 
approach in hand, we sought to determine the extent to which each compound retained the 
typical binding properties of PA effectors. To do so, we screened the binding of the C2 
domain of PKCα to lipid vesicles containing the different PA analogues at 20 mol %. 
Studies employed an isolated C2 binding domain to increase the specificity for PA since full 
length PKCα contains multiple binding domains that target different lipids and assist in 
membrane association. For binding studies, a surface plasmon resonance (SPR) assay was 
implemented using POPC/POPE/PA (40:40:20) vesicles containing the various PA probes as 
an active surface (see depiction of liposome composition in Figure 2). We first performed 
binding experiments with vesicles containing synthetic unmodified POPA, as the binding of 
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PKCα-C2 to PA-containing vesicles has been well documented.72 In this study, the binding 
of PKCα-C2 to these vesicles yielded a Kd value of 440 ± 50 nM, as shown in Table 1. Next, 
we systematically analyzed the binding efficacy of the described PA reporters. The resulting 
binding affinities for each compound are indicated Table 1. In addition, an overlay of 
representative binding curves corresponding to vesicles containing synthetic PA (POPA) and 
dansyl-PA (12b) is shown in Figure 3, and raw SPR sensorgrams are shown in 
supplementary figure S51.
The results from these membrane binding studies indicate that each of the described PA 
probes displayed similar properties to POPA in the binding of PKCα-C2, with Kd values 
ranging from 510 to 850 nM. PA probes derivatized with rhodamine (12d, 510 nM), the 
bifunctional benzophenone/azide tag (12f, 520 nM) and benzophenone (12e, 570 nM), 
yielded the strongest binding affinities, which were comparable to POPA (440 nM). While 
the others, napthyl PA (12a, 780 nM) dansyl PA (12b, 800 nM), and coumarin PA (12c, 850 
nM) yielded slightly weaker affinities, all are less than two times that of POPA. With these 
results, there doesn’t appear to be a clear trend that relates binding affinities to the 
physiochemical properties of the appended reporter groups.
These studies employing 20 mol% PA in liposomes proved useful in demonstrating the 
reliability of our synthetic PA probes, however, the physiological concentrations of PA in 
cellular membranes are thought to be much lower. To validate the significance and 
physiological relevance of PA binding, we monitored the interaction of PKCα-C2 with 
vesicles containing 5 mol% (POPC:POPE:PA 55:40:5) of the different PA analogues. As 
shown in Table 1, PKCα-C2 bound synthetic PA and corresponding PA probes with nearly 
the same affinity. Moreover, PKCα-C2 affinity for vesicles containing 5 mol% PA probes 
was comparable to that for vesicles containing 20 mol% PA probes, suggesting PKCα-C2 
binding is saturated at 5 mol% PA. Future studies will be performed to further understand 
the presentation of these compounds in a membrane environment and the effect on protein 
binding properties.
Conclusion
Herein, we describe an efficient approach for the generation of a range of derivatized PA 
probes through modular functionalization of core azide-tagged scaffold 2 via click 
chemistry. Despite the fact that bulky reporter moieties are introduced onto the PA 
headgroup using this approach, the first quantitative analysis of these compounds indicates 
their ability to mimic PA in the recruitment of effectors to membrane surfaces. These studies 
demonstrate the relevance of these PA probes for use as robust reporters of PA activity in 
biological processes. Furthermore, the installation of reporter moieties at the lipid headgroup 
is expected to place the appended tag in proximity to proteins bound to the membrane 
surface (see schematic depiction of expected tag presentation in Figure 1B). The use of click 
chemistry is also beneficial in this regard, as the polar triazoles that result, when presented 
on lipids, are believed to preferentially localize to the aqueous environment rather than the 
hydrophobic membrane core.57 As a result, the triazole is anticipated to enhance 
presentation of the appended tag at the hydrophilic membrane surface. Headgroup 
modification, in cases where the perturbation of protein binding is limited, is expected to 
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enhance challenging applications such as FRET-based detection of proteins bound to a 
tagged lipid, and protein–lipid photo-cross-linking, which require the tag to be in close 
proximity to a bound protein.
Currently, we are extending studies employing these PA probes in several ways. First, we are 
continuing the characterization of these compounds to further understand their efficacy in 
mimicking PA in terms of physiochemical properties, presentation in a membrane 
environment, and protein binding properties. In addition, we are applying these newly 
developed analogues as chemical tools to characterize the activities of PA via a range of 
approaches. These probes can be incorporated into liposomes as a model system for 
characterizing the details of protein–lipid binding events at the molecular level. Furthermore, 
the described probes can be modified for in vivo analysis of PA activities along the same 
lines as previous probe-based approaches. Probe 12f will be employed to purify and identify 
PA-binding receptors in similar fashion to recent reports.51 Finally, we are also advancing 
our modular probe strategy to develop biologically active analogues corresponding to other 
important signaling lipids.
Experimental
General
Generally, reagents were purchased from Acros or Aldrich and used as received. Cbz-
Lys(Boc)-OMe was purchased from Chem-Impex International (Wood Dale, IL). Dry 
solvents were obtained from a Pure Solv solvent delivery system purchased from Innovative 
Technology, Inc. Column chromatography was performed using 230 – 400 mesh silica gel 
purchased from Sorbent Technologies. NMR spectra were obtained using a Bruker AC250 
spectrometer updated with a TecMag data collection system, a Varian Mercury 300 
spectrometer, and a Bruker Avance 400 spectrometer. Mass spectra were obtained with 
JEOL DART-AccuTOF spectrometer with high resolution capabilities. Optical rotation 
values were obtained using a Perkin-Elmer 241 polarimeter. HPLC data was obtained using 
an HP series 1100 HPLC with an Alltech Lichrosphere SI 60 5U column with HPLC grade 
solvents purchased from Fischer. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphatidic acid (POPA) were purchased from Avanti 
Polar Lipids, Inc. (Alabaster, AL).
(2R,3R)-diethyl 1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate (4)
Fully protected tartrate 4 was obtained following a procedure modified form that used to 
access the enantiomer of this structure.52 Diethyl-L-tartrate 3 (4.05 g, 19.6 mmol) was 
dissolved in toluene (130 mL). To this stirring solution was added cyclopentanone (8.7 mL, 
98 mmol) and p-toluenesulfonic acid (373 mg, 1.96 mmol). A Dean–Stark trap was attached 
and the reaction was heated at 130 °C overnight. Solid sodium bicarbonate (329 mg, 20%) 
was added and stirring was continued for 10 min. The reaction mixture was filtered and the 
filtrate was condensed under reduced pressure. Column chromatography with silica gel and 
a gradient solvent system of 0–20% ethyl acetate to hexanes afforded 4 as a yellow oil (4.19 
g, 79%).
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Characterizations matched the enantiomer of 4 but for the change in sign of the optical 
rotation.52 [α]D296K – 31.5(c = 2.92, CHCl3); 1H NMR (300 MHz, CDCl3) δ 4.71 (s, 2H), 
4.26 (q, J = 7.2 MHz, 4H), 2.03–1.67 (m, 8H), 1.30 (t, J = 7.2 MHz, 6H); 13C NMR (75.5 
MHz, CDCl3) δ 169.7, 123.3, 77.0, 61.9, 36.6, 23.5, 14.1; HRMS [M + H]+ calcd: 
273.13381, found: 273.13516.
(2S,3S)-1,4-dioxaspiro[4.4]nonane-2,3-diyldimethanol (5)
Protected tartrate 5 was obtained using a procedure modified from reports of the 
enantiomer52 and a similar compound.53 Diester 4 (2.5 g, 9.18 mmol), dissolved in 
anhydrous THF (8 mL), was added dropwise to a solution of lithium aluminum hydride (700 
mg, 18.36 mmol) in anhydrous THF at 0 °C under nitrogen. After the addition was 
complete, stirring was continued for 1 h at 0 °C and then at room temperature for an addition 
1 h. The solution was cooled to 0 °C and the nitrogen was removed. Carefully, water (1 mL), 
10% NaOH (1 mL), and water (2 mL) were added to quench the reaction. Stirring was 
continued for 30 min at room temperature. Anhydrous magnesium sulfate was added and 
stirring was continued for 30 min. The solution was filtered and concentrated under reduced 
pressure. Column chromatography with silica gel and a gradient solvent system of 0–10% 
methanol to ethyl acetate afforded 5 as a clear oil which solidified upon refrigeration (1.70 g, 
99%).
Characterizations matched the enantiomer of 5 but for the change in sign of the optical 
rotation.52 [α]D296K – 6.50 (c = 1.692, CHCl3); 1H NMR (300 MHz, CDCl3) δ 3.97–3.94 
(m, 2H), 3.81–3.69 (m, 4H), 2.30–2.05 (m, 2H), 1.89–1.60 (m, 8H); 13C NMR (75.5 MHz, 
CDCl3) δ 119.4, 78.0, 62.3, 37.4, 23.4; HRMS [M + H]+ calcd: 189.11268, found: 
189.11238.
((2S,3S)-3-azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methanol (6)
Azide 6 was obtained following procedures reported for similar compounds.53,73 Diol 5 (720 
mg, 3.83 mmol) was suspended in dichloromethane (20 mL). With stirring, silver (I) oxide 
(1.33 g, 5.75 mmol), tosyl chloride (803 mg, 4.21 mmol) and finely crushed potassium 
iodide (64 mg, 0.383 mmol) were added. The resulting solution was stirred at room 
temperature for 2 h and then filtered through a plug of silica gel with 100% ethyl acetate as 
the eluant. The filtrate was concentrated under reduced pressure, and then DMF (40 mL) and 
sodium azide (622 mg, 9.58 mmol) were added. The solution was stirred at 85 °C overnight, 
concentrated, extracted with chloroform (2 × 100 mL), dried with magnesium sulfate, and 
concentrated under reduced pressure. Column chromatography with silica gel and 50% ethyl 
acetate to hexane as eluant afforded 6 as a clear oil (636 mg, 78%).
[α]D296K – 57.8 (c = 1.492, CHCl3); 1H NMR (300 MHz, CDCl3) δ 4.05–3.90 (m, 2H), 
3.81–3.62 (m, 2H), 3.55–3.51 (m, 1H), 3.30–3.33 (m, 1H), 2.65 (bs, 1H), 1.89–1.67 (m, 8H); 
13C NMR (75.5 MHz, CDCl3) δ 119.8, 78.5, 76.1, 62.0, 52.0, 37.3, 37.2, 23.5, 23.3; HRMS 
[M – N2 + H]+ calcd: 186.11302, found: 186.11384.
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((2S,3S)-3-(azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methyl dibenzyl phosphate (8)
Azido alcohol 6 (425 mg, 1.99 mmol) was dissolved in anhydrous dichloromethane. 1H-
tetrazole (13.3 mL, 5.98 mmol, 0.45 M stock) was added and the solution was cooled to 
0 °C under nitrogen. Dibenzyldiisopropylphosphoramidite (7, 721 µL, 2.19 mmol) was then 
added dropwise. Stirring was continued for 10 min at 0 °C and then at room temperature for 
1 h. At this point the reaction solution was cooled to 0 °C and m-chloroperoxybenzoic acid 
(1.81 g, 5.98 mmol, 57% purity) was added and stirring was continued for 1.5 h. The 
reaction was quenched with the addition of saturated sodium bicarbonate, extracted with 
dichloromethane (2 × 100 mL), dired with magnesium sulfate, and concentrated under 
reduced pressure. Column chromatography with silica gel and 50% ethyl acetate to hexane 
as eluant afforded 8 as a pale yellow oil (803 mg, 85%).
[α]D296K – 24.3 (c = 1.68, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.42–7.32 (m, 10H), 
5.11–4.99 (m, 4H), 4.09–3.87 (m, 4H), 3.43–3.37 (m, 1H), 3.24–3.18 (m, 1H), 1.89–1.60 (m, 
8H); 13C NMR (75.5 MHz, CDCl3) δ 135.7, 135.6, 128.7, 128.6, 128.0, 120.2, 76.8, 76.0, 
75.9, 69.6, 69.5, 66.7, 66.6, 51.8, 37.3, 37.1, 23.5, 23.4; 31P NMR (121.5 MHz, CDCl3) δ 
0.143; HRMS [M – N2 + H]+ calcd: 446.17325, found: 446.17276.
(2S,3S)-4-azido-2,3-dihydroxybutyl dibenzyl phosphate (9)
Phosphotriester 8 (1.07 g, 2.26 mmol) was dissolved in methanol (15 mL). With stirring was 
added p-toluenesulfonic acid (43 mg, 0.226 mmol). The solution was stirred at room temp 
overnight and quenched with saturated sodium bicarbonate and extracted with chloroform (2 
× 100 mL), dried with magnesium sulfate, and concentrated under reduced pressure. Column 
chromatography with silica gel and a gradient solvent system of 80–100% ethyl acetate to 
hexanes afforded 9 as a clear oil (482 mg, 52%).
[α]D296K + 8.04 (c = 1.48, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.37–7.31 (m, 10H), 
5.05–5.02 (m, 4H), 4.04–4.00 (m, 2H), 3.72–3.69 (m, 2H), 3.43–3.26 (m, 4H); 13C NMR 
(75.5 MHz, CDCl3) δ 135.4, 135.3, 128.8, 128.7, 128.1, 70.2, 70.1, 69.9, 69.8, 69.7, 68.54, 
68.46, 53.3; 31P NMR (121.5 MHz, CDCl3) δ 0.928; HRMS [M – N2 + H]+ calcd: 
380.12630, found: 380.12495.
(2S,3S)-1-azido-4-(bis(benzyloxy)phosphoryloxy)butane-2,3-diyl distearate (2)
Diol 9 (482 mg, 1.18 mmol), stearic acid (1.01 g, 3.55 mmol), dicyclohexylcarbodiimide 
(732 mg, 3.55 mmol) and 4-dimethylaminopyridine (144 mg, 1.18 mmol) were dissolved in 
dichloromethane (12 mL) and stirred at room temperature overnight. The reaction was 
filtered using ethyl acetate and concentrated under reduced pressure. Column 
chromatography with silica gel and a gradient solvent system of 10–30% ethyl acetate to 
hexanes afforded 2 as a white solid (820 mg, 74%).
[α]D296K – 4.26 (c = 1.315, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.35–7.26 (m, 10H), 
5.20 (bs, 2H), 5.04–5.01 (m, 4H), 4.13–3.90 (m, 2H), 3.45–3.28 (m, 2H), 2.35–2.24 (m, 4H), 
1.65–1.58 (m, 4H), 1.26 (bs, 56H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR (75.5 MHz, CDCl3) δ 
172.7, 172.6, 135.6, 135.5, 128.7, 128.6, 128.03, 127.99, 70.0, 69.9, 69.7, 69.6, 69.5, 65.1, 
65.0, 50.6, 34.0, 31.9, 29.72, 29.68, 29.5, 29.4, 29.3, 29.1, 24.81, 24.78, 22.7, 14.1; 31P 
Smith et al. Page 9
Mol Biosyst. Author manuscript; available in PMC 2018 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
NMR (121.5 MHz, CDCl3) δ 0.038; MALDI–HRMS [M + Na]+ calcd: 962.6358, found: 
962.6332.
Rhodamine-Alkyne Conjugate (10d)
Lissamine Rhodamine B sulfonyl chloride (141 mg, 0.244 mmol) was dissolved in DMF (10 
mL). Propargyl amine (17 μL, 0.244 mmol) and triethyl amine (170 µL, 1.22 mmol) were 
added with stirring. Stirring was continued in the dark at room temperature overnight at 
which time the solvent was removed under reduced pressure. Column chromatography with 
silica gel and a gradient solvent system of 2–7% methanol to dichloromethane afforded 10d 
as a purple solid (55 mg, 38%).
1H NMR (300 MHz, CDCl3) δ 8.74 (m, 1H), 8.13–8.10 (m, 1H), 7.37 (d, J = 8.1 Hz, 1H), 
7.15 (d, J = 9.3 Hz, 2H), 6.93–6.89 (m, 2H), 6.82–6.81 (m, 2H), 3.93 (d, J = 2.4 Hz, 2H), 
3.64 (q, J = 7.2 Hz, 8H), 2.44 (t, J = 2.5 Hz, 1H), 1.33 (t, J = 7.2 Hz, 12H); 13C NMR (62.9 
MHz, CDCl3) δ 158.3, 157.4, 156.0, 146.6, 142.7, 134.4, 133.0, 130.7, 128.6, 127.6, 114.5, 
114.1, 96.2, 78.6, 73.5, 46.2, 32.8, 12.7; MALDI–HRMS [M + Na]+ calcd: 618.1703, found: 
618.1699
Benzophenone-Lys(Boc)-OMe (14)
Cbz-Lys(Boc)-OMe (13, 535 mg, 1.36 mmol) was dissolved in methanol (15 mL). 
Palladium (II) hydroxide (10% wt) was added with stirring. A hydrogen atmosphere was 
established and stirring was continued overnight. The reaction mixture was filtered through 
celite and washed with methanol and the solvent was removed under reduced pressure. The 
residue was dissolved in DMF (10 mL). With stirring 4-benzoylbenzoic acid (308 mg, 1.36 
mmol), 4-dimethylaminopyridine (199 mg, 1.63 mmol), and N-methylmorpholine (523 µL, 
4.76 mmol) were added. After 5 min EDCI·HCl (313 mg, 1.63 mmol) was added and 
stirring was continued 7 h. The solvent was removed under reduced pressure and column 
chromatography with silica gel and a solvent system of 50% ethyl acetate to hexanes 
afforded 14 as a white foam (561 mg, 88%).
[α]D296K + 8.89(c = 5.544, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.96 ( d, J = 8.4 Hz, 
2H), 7.84–7.77 (m, 4H), 7.62 (t, J = 7.5 Hz, 1H), 7.52–7.47 (m, 2H), 7.26 (d, J = 7.5 Hz, 
1H), 4.81–4.77 (m, 2H), 3.78 ( s, 3H), 3.13–3.11 (m, 2H), 2.00–1.40 (m, 15H); 13C NMR 
(100.6 MHz, CDCl3) δ 195.9, 172.9, 166.5, 156.2, 140.3, 137.1, 137.0, 132.9, 130. 23, 
130.20, 128.4, 127.2, 79.1, 52.7, 52.5, 40.0, 31.9, 29.7, 28.4, 22.6; HRMS [M - Boc + 2H]+ 
calcd: 369.18143, found: 369.18007
Benzophenone-Lys(Boc)-Alkyne (10f)
Compound 14 (561 mg, 1.20 mmol) was dissolved in methanol (5 mL). With stirring was 
added 2 N NaOH (5 mL). Stirring was continued 20 min and TLC analysis showed no 
starting material. The solution was neutralized with Dowex®50WX8–200 H+ resin to pH ~4. 
The solution was filtered and the filtrate concentrated under reduced pressure. The residue 
was washed with toluene, concentrated, and dried under high vacuum 5 h. The residue was 
then dissolved in dichloromethane (15 mL) and with stirring propargyl amine (99 µL, 1.44 
mmol), 4-dimethylaminopyridine (146 mg, 1.20 mmol), EDCI∙HCl (276 mg, 1.44 mmol) 
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and N-methylmorpholine (395 µL, 3.59 mmol) were added. Stirring was continued overnight 
at room temperature at which time the solvent was removed under reduced pressure. Column 
chromatography with silica gel and a gradient solvent system of 50–80% ethyl acetate to 
hexanes afforded 10f as a white solid (550 mg, 93%, 2 steps).
[α]D296K + 1.07(c = 0.935, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.96–7.92 (m, 2H), 
7.81–7.74 (m, 4H), 7.61–7.44 (m, 5H), 4.82–4.75 (m, 2H), 4.12–3.96 (m, 2H), 3.08–3.07 
(m, 2H), 2.19 (t, J = 2 Hz, 1H), 2.00–1.77 (m, 2H), 1.59–1.38 (m, 12H); 13C NMR (75.5 
MHz, CDCl3) δ 195.9, 171.8, 166.8, 156.2, 140.3, 136.9, 136.8, 132.9, 130.1, 130.0, 128.5, 
127.3, 79.3, 79.1, 71.7, 53.5, 40.1, 32.3, 29.6, 29.2, 28.4, 22.7; HRMS [M - Boc + 2H]+ 
calcd: 392.19742, found: 392.19514
General Procedure for Click Chemistry Derivatization to Produce Phosphotriesters 11a–e
Compound 2 and derivatized alkynes (10a–e) were dissolved in THF (1.5–2 mL). Copper 
sulfate pentahydrate and sodium ascorbate were added along with H2O (0.5 mL). The 
solution was stirred at room temperature overnight at which point the solvent was removed 
under reduced pressure. Column chromatography with silica gel afforded compounds 11a–e. 
Due to the amphipathic nature of the phosphotriesters, the integration values in the proton 
NMR spectra sometimes varied slightly from the expected values.
Naphthyl Phosphotriester (11a)
Alkyne 10a (33.7 mg, 0.151 mmol), 2 (141.6 mg, 0.151 mmol), copper sulfate pentahydrate 
(113 mg, 0.453 mmol), and sodium ascorbate (179 mg, 0.906 mmol) were utilized. Column 
chromatography with a gradient solvent system of 70–100% ethyl acetate to hexanes 
afforded 11a as a white solid (151 mg, 86%).
[α]D296K – 4.41 (c = 3.79, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.80–7.75 (m, 3H), 7.69 
(s, 1H), 7.48–7.43 (m, 3H), 7.36–7.33 (m, 11H), 6.52 (t, J = 5.4 Hz, 1H), 5.44–5.39 (m, 1H), 
5.03–4.97 (m, 5H(1 + 4 H)), 4.43–4.41 (m, 4H), 4.18–4.06 (m, 2H), 3.71 (s, 2H), 2.29–2.18 
(m, 4H), 1.56–1.48 (m, 4H), 1.25 (bs, 56H), 0.88 (t, J = 6 Hz, 6H); 13C NMR (75.5 MHz, 
CDCl3) δ 172.6, 172.2, 171.1, 144.9, 135.5, 135.4, 133.5, 132.4, 132.2, 128.7, 128.6, 128.1, 
128.0, 127.96, 127.3, 126.2, 125.9, 123.5, 69.65, 69.57, 69.1, 64.82, 64.81, 49.9, 49.8, 43.6, 
34.9, 33.9, 33.8, 31.9, 29.71, 29.67, 29.5, 29.4, 29.3, 29.12, 29.07, 24.8, 24.7, 22.7, 14.1; 31P 
NMR (121.5 MHz, CDCl3) δ -0.001; MALDI–HRMS [M + Na]+ calcd: 1185.7355, found: 
1185.7310.
Dansyl Phosphotriester (11b)
Alkyne 10b (33.4 mg, 0.116 mmol), 2 (109 mg, 0.116 mmol), copper sulfate pentahydrate 
(87 mg, 0.348 mmol), and sodium ascorbate (138 mg, 0.696 mmol) were utilized. Column 
chromatography with a gradient solvent system of 50–80% ethyl acetate to hexanes afforded 
11b as a green glass (121 mg, 85%).
[α]D296K – 4.40 (c = 1.796, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 8.7 Hz, 
1H), 8.29–8.25 (m, 2H), 7.53 (q, J = 7.9 Hz, 2H), 7.34 (bs, 11H), 7.18 (d, J = 7.2 Hz, 1H), 
5.52 (bs, 1H), 5.40–5.35 (m, 1H), 5.08–4.97 (m, 5H(1 + 4H)), 4.39–4.37 (m, 2H), 4.17–4.05 
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(m, 4H), 2.89 (s, 6H), 2.30–2.21 (m, 4H), 1.56–1.50 (m, 4H), 1.25 (bs, 56H), 0.88 (t, J = 6.6 
Hz, 6H); 13C NMR (75.5 MHz, CDCl3) δ 172.6, 172.3, 151.9, 144.4, 135.45, 135.46, 134.6, 
130.5, 129.9, 129.6, 129.5, 128.7, 128.6, 128.5, 128.03, 127.99, 123.4, 123.1, 118.8, 115.3, 
69.7, 69.6, 69.1, 64.92, 64.86, 49.8, 45.4, 38.7, 33.9, 33.8, 31.9, 29.72, 29.67, 29.5, 29.4, 
29.29, 29.27, 29.13, 29.07, 24.8, 24.7, 22.7, 14.1; 31P NMR (121.5 MHz, CDCl3) δ -0.058; 
MALDI–HRMS [M + Na]+ calcd: 1250.7290, found: 1250.7317.
Coumarin Phosphotriester (11c)
Alkyne 10c (36.1 mg, 0.159 mmol), 2 (149.3 mg, 0.159 mmol) copper sulfate pentahydrate 
(119 mg, 0.477 mmol), and sodium ascorbate (189 mg, 0.954 mmol) were employed. 
Column chromatography with a gradient solvent system of 70–100% ethyl acetate to 
hexanes afforded 11c as a white solid (153 mg, 83%).
[α]D296K – 6.96 (c = 6.132, CHCl3); 1H NMR (300 MHz, CDCl3) δ 9.28–9.25 (m, 1H) 8.90 
(s, 1H), 7.69–7.64 (m, 2H), 7.58 (s, 1H), 7.41–7.34 (m, 12H), 5.49–5.44 (m, 1H), 5.09–4.98 
(m, 5H(1+4H)), 4.73–4.71 (m, 2H), 4.49–4.47 (m, 2H), 4.19–4.09 (m, 2H), 2.30–2.22 (m, 
4H), 1.57–1.42 (m, 4H), 1.25 (bs, 56H), 0.88 (t, J = 6.5 Hz, 6H); 13C NMR (100.6 MHz, 
CDCl3) δ 172.5, 172.2, 161.7, 161.1, 154.5, 148.4, 144.9, 135.6, 135.5, 134.2, 129.8, 128.7, 
129.0, 125.3, 123.3, 115.5, 118.3, 116.7, 69.7, 69.2, 64.9, 49.9, 35.5, 34.0, 33.8, 32.9, 29.7, 
29.5, 29.4, 29.3, 29.2, 24.8, 24.7, 22.7, 14.1; 31P NMR (121.5 MHz, CDCl3) δ 0.027; 
MALDI–HRMS [M + Na]+ calcd: 1189.6940, found: 1189.6920.
Rhodamine Phosphotriester (11d)
Alkyne 10d (21.4 mg, 0.036 mmol), 2 (34 mg, 0.036 mmol) copper sulfate pentahydrate (27 
mg, 0.108 mmol), and sodium ascorbate (43 mg, 0.215 mmol) were used. Column 
chromatography with 10% methanol / chloroform as eluant afforded 11d as a pink solid (44 
mg, 80%).
No optical rotation was obtained due to the high propensity of the compound to stain; 1H 
NMR (300 MHz, CDCl3) δ 8.52 (s, 1H), 7.93–7.91 (m, 2H), 7.30 (bs, 12H), 7.10 (d, J = 7.5 
Hz, 1H), 6.90 (d, J = 8.7 Hz, 2H), 6.63–6.62 (m, 3H), 5.47 (bs, 1H), 5.01–4.97 (m, 5H(1 
+ 4H)), 4.73–4.69 (m, 1H), 4.58–4.45 (m. 3H), 4.16 (s, 2H), 3.65–3.52 (m, 8H), 2.21–2.18 
(m, 4H), 1.47–1.45 (m, 4H), 1.31–1.20 (m, 68H), 0.88 (t, J = 6.6 Hz, 6H); 13C NMR (100.6 
MHz, CDCl3) δ 172.6, 172.3, 159.0, 157.8, 155.7, 155.5, 147.4, 142.3, 135.83, 135.76, 
133.73, 133.67, 133.3, 129.6, 128.6, 128.5, 128.4, 128.0, 127.4, 127.2, 125.1, 114.3, 113.7, 
113.6, 95.6, 70.0, 69.9, 69.63, 69.57, 69.5, 69.4, 68.9, 65.2, 50.1, 45.8, 38.8, 34.1, 33.9, 
31.9, 29.7, 29.5, 29.4, 29.1, 24.8, 24.7, 22.7, 14.1, 12.6; 31P NMR (121.5 MHz, CDCl3) δ 
-0.247; MALDI–HRMS [M + Na]+ calcd: 1557.8169, found: 1557.8251.
Benzophenone Phosphotriester (11e)
Alkyne 10e (38 mg, 0.144 mmol), 2 (123 mg, 0.131 mmol), copper sulfate pentahydrate (98 
mg, 0.392 mmol), and sodium ascorbate (155 mg, 0.785 mmol) were used. Column 
chromatography with a gradient solvent system of 70–100% ethyl acetate to hexanes 
afforded 11e as a white solid (135 mg, 86%).
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[α]D296K – 5.27 (c = 2.544, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 7.8 Hz, 
2H), 7.83–7.76 (m, 4H), 7.64–7.58 (m, 2H), 7.48 (t, J = 7.7 Hz, 3H), 7.33 (bs, 10H), 5.49–
5.43 (m, 1H), 5.11–4.96 (m, 5H(1 + 4H)), 4.78–4.71 (m, 2H), 4.55–4.49 (m, 2H), 4.19–4.09 
(m, 2H), 2.30–2.22 (m. 4H), 1.56–1.49 (m, 4H), 1.25 (bs, 56H), 0.88 (t, J = 6.5 Hz, 6H); 13C 
NMR (100.6 MHz, CDCl3) δ 195.8, 172.6, 172.2, 166.5, 140.1, 137.2, 137.1, 135.54, 
135.47, 132.8, 130.0, 128.6, 128.4, 128.0, 127.97, 127.1, 123.6, 69.7, 69.6, 69.2, 64.9, 64.8, 
50.0, 35.5, 34.0, 33.8, 31.9, 29.7, 29.5, 29.4, 29.3, 29.14, 29.10, 24.8, 24.7, 22.7, 14.1; 31P 
NMR (121.5 MHz, CDCl3) δ -0.058; MALDI–HRMS [M + H]+ calcd: 1203.7485, found: 
1203.7488.
Bifunctional benzophenone/azido Phosphotriester (11f)
Alkyne 10f (84 mg, 0.171 mmol) was dissolved in dichloromethane (2 mL) and with stirring 
was added trifluoroacetic acid (2 mL). Stirring was continued for 2 h and the solvent was 
removed under reduced pressure and placed under high vacuum for 2 h. The residue was 
dissolved in THF (1.5 mL) and 2 (161 mg, 0.171 mmol) was added along with copper 
sulfate pentahydrate (43 mg, 0.171 mmol), sodium ascorbate (68 mg, 0.342 mmol), and H2O 
(0.5 mL). Stirring was continued overnight at room temperature at which point the solvent 
was removed under reduced pressure and placed under high vacuum 2 h. This residue was 
dissolved in anhydrous DMF (3 mL) and 6-azidohexanoic acid71 (32 mg, 0.205 mmol) was 
added. 4-Dimethylaminopyridine (21 mg, 0.171 mmol), EDCI∙HCl (72 mg, 0.376 mmol), 
and N-methylmorpholine (94 µL, 0.855 mmol) were added and stirring was continued 
overnight at room temperature at which point the solvent was removed under reduced 
pressure. Column chromatography with silica gel and a gradient solvent system of 30–50% 
acetone to chloroform afforded 11f as a white solid (110 mg, 44%, 3 steps).
[α]D296K – 4.91 (c = 4.36, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 8.4 Hz, 2H), 
7.80 (t J = 8.4 Hz, 4H), 7.64–7.47 (m, 6H), 7.34 (bs, 10H), 6.16–6.12 (m, 1H), 5.47–5.42 (m, 
1H), 5.07–4.96 (m, 5H(1 + 4H)), 4.68–4.66 (m, 1H), 4.52–4.52 (m, 4H), 4.13–4.07 (m, 2H), 
3.26–3.19 (m, 4H), 2.30–2.23 (m, 4H), 2.12 (t, J = 7.5 Hz, 2H), 1.96–1.84 (m, 2H), 1.63–
1.24 (m, 70H), 0.88 (t J = 6.5 Hz, 6H); 13C NMR (100.6 MHz, CDCl3) δ 195.8, 173.2, 
172.6, 173.3, 171.8, 166.7, 144.8, 140.3, 137.0, 135.5, 135.4, 132.9, 130.1, 130.0, 128.72, 
128.67, 128.4, 128.0, 127.96, 127.3, 123.3, 69.72, 69.67, 69.2, 64.9, 53.6, 51.2, 49.9, 38.6, 
36.4, 35.1, 34.0, 33.9, 31.9, 29.7, 29.6, 29.4, 29.3, 29.14, 29.06, 28.6, 26.4, 25.2, 24.80, 
24.76, 22.7, 22.5, 14.1; 31P NMR (121.5 MHz, CDCl3) δ -0.254; MALDI–HRMS [M + Na]
+
 calcd: 1492.8999, found: 1492.9028.
General Procedure for Deprotection of Phosphotriesters to Access PA Analogues 1b / 12a–
f
Phosphotriesters 2 / 11a–f were dissolved in dichloromethane at 0 °C under argon. 
Bromotrimethylsilane was added and stirring was continued at room temperature for 1 h. 
Solvent was removed under reduced pressure and the residue was placed on a high vacuum 
line to remove any residual solvents. Methanol (2 mL) was added and the solution was 
stirred at room temperature for 1 h. The solid that formed was collected via filtration. The 
solid was dissolved in methanol–chloroform (1:4) and extracted with 8 mM ammonium 
acetate. The organic layer was concentrated under reduced pressure to afford 1b / 12a–f.
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Azido PA (1b)
Azido phosphotriester 2 (65 mg, 0.069 mmol), dichloromethane (2.45 mL), and 
bromotrimethylsilane (0.55 mL) afforded 1b as a white solid (30 mg, 56%). 1H NMR (300 
MHz, CDCl3 : CD3OD (1:1)) δ 5.29 (bs, 2H), 4.09 (bs, 2H), 3.61–3.52 (m, 2H), 2.38–2.37 
(m, 4H), 1.64 (bs, 4H), 1.27 (bs, 56H), 0.89 (t, J = 6.3 Hz, 6H); 31P NMR showed no 
resonance in any solvent tried; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 804.5238, found: 
804.5143.
Naphthyl PA (12a)
Naphthyl phosphotriester 11a (67 mg, 0.058 mmol), dichloromethane (1.64 mL), and 
bromotrimethylsilane (0.36 mL) afforded 12a as a brownish solid (40 mg, 70%).
31P NMR (121.5 MHz, CDCl3) δ 1.44; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 
1027.6235, found: 1027.6273.
Dansyl PA (12b)
Dansyl phosphotriester 11b (80 mg, 0.065 mmol), dichloromethane (1.64 mL), and 
bromotrimethylsilane (0.36 mL) afforded 12b as a green solid (74 mg, quantative yield).
31P NMR (121.5 MHz, CDCl3) δ 1.09; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 
1092.6171, found: 1092.6128.
Coumarin PA (12c)
Coumarin phosphotriester 11c (60 mg, 0.051 mmol), dichloromethane (1.64 mL), and 
bromotrimethylsilane (0.36 mL) afforded 12c as a white solid (40 mg, 78%).
31P NMR (121.5 MHz, CDCl3) δ 1.39; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 
1031.5821, found: 1031.5857.
Rhodamine PA (12d)
Rhodamine phosphotriester 11d (44mg, 0.029 mmol), dichloromethane (1.64 mL), and 
bromotrimethylsilane (0.36 mL) Column chromatography with silica gel and a solvent 
system of 7 chloroform : 2.5 methanol : 0.5 water was necessary to purify the phosphate. 
The resulting solid was dissolved in methanol–chloroform (1:4) and extracted with 8 mM 
ammonium acetate. The organic layer was concentrated under reduced pressure to afford 
12d as a purple solid (34 mg, 85%).
31P NMR no resonance could be detected in any solvent tried; MALDI–HRMS [M - NH4 
+ 2Na]+ calcd: 1399.7049, found: 1399.6963.
Benzophenone PA (12e)
Benzophenone phosphotriester 11e (41.5 mg, 0.035 mmol), dichloromethane (1.64 mL), and 
bromotrimethylsilane (0.36 mL) afforded 12e as a pinkish white solid (26 mg, 73%).
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31P NMR (121.5 MHz, CDCl3) δ 1.25; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 
1067.6185, found: 1067.6116.
Bifunctional Benzophenone/Azido PA (12f)
Bifunctional benzophenone/azido phosphotriester 11f (52 mg, 0.035 mmol), 
dichloromethane (1.64 mL), and bromotrimethylsilane (0.36 mL) afforded 12f as a white 
solid (38 mg, 83%).
31P NMR (121.5 MHz, CDCl3) δ 1.12; MALDI–HRMS [M - NH4 + 2Na]+ calcd: 
1334.7880, found: 1334.7890.
PA Binding Analysis with Surface Plasmon Resonance
All surface plasmon resonance (SPR) binding measurements were performed at room 
temprature (25°C). PA lipid stocks were dissolved in a chloroform:methanol (80:20) mixture 
from which liposomes were prepared as POPC:POPE:PA (40:40:20) for different PA 
compounds. Aliquots of lipid mixtures to prepare a final concentration of 0.5 mg/ml of 
vesicles were dried under nitrogen and rehydrated with 500 µl binding buffer (25 mM Tris 
HCl pH 7.4, 150 mM NaCl, 10 µM CaCl2 and 1 mM DTT). Lipid solutions were vortexed 
for 15 min and sonicated for 15 min. Lipid vesicles were then passed 19 times through a 100 
nm polycarbonate membrane in an Avanti Mini-Extruder at room temperature. The liposome 
coating of the L1 sensor chip (GE Healthcare) has been described in detail previously.74,75 
Briefly, the sensor chip surface was washed and then coated by injecting 85 µl of vesicles 
containing various analogs of PA at a 5 µl/min flow rate to yield a response of 5,000 
resonance units (RU). Each lipid layer was stabilized by injecting 10 µl of 50 mM NaOH 
(the regeneration solution) three times at 100 µl/min flow rate. Typically, no decrease in lipid 
signal was seen after the first injection. Various concentrations of PKCα-C2 (within a 10-
fold range of Kd) were injected to study the equilibrium binding and viability of synthetic 
analogs of PA. PKCα-C2 was expressed and purified as previously described.76 For 
Equilibrium SPR measurements, the flow rate was set at 10 µl/min to allow sufficient time 
for the association phase, which in turn allows RU values to reach saturating response values 
(Req). Following binding of each respective injection of PKCα-C2, the lipid layer was 
regenerated to baseline with two 30 µl pulses of 50 mM NaOH injected at a flow rate of 30 
µl/min. Following collection of three data sets for each PA analogue, Req values were plotted 
versus respective protein concentrations (C), and the Kd value was calculated by a non-linear 
least squares analysis of the binding isotherm using an equation, Req = Rmax/(1 + Kd/C),75 
where Rmax is a theoretical maximum Req value. Validation of Kd values determined from 
equilibrium binding response values was performed by analyzing sensorgrams with 
BIAevaluation software to determine rate constants of association (ka) and (kd) as described 
previously,78 assuming a 1:1 protein-membrane surface binding, because all kinetic 
sensorgrams agreed with this model. Furthermore, Kd values determined by kinetic fits were 
similar (±15%) to Kd values obtained through equilibrium binding analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PA membrane presentation and protein binding
A. PA presentation in the membrane and charge reinforced H-bond formed during protein 
binding. Figure is adapted from reference 43. B. Expected presentation of tagged PA probes 
in the membrane.
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Figure 2. Modular azide-tagged scaffolds corresponding to DAG and PA and expected 
presentation in liposomes employed for binding studies
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Figure 3. Representative binding curves for the binding of PKCα-C2 to membranes containing 
different PAs
SPR measurements were used to determine Kds of PKCα-C2 for POPC/POPE/PA 
(40:40:20) vesicles where PA represents synthetic PAs reported in this manuscript. PKCα-
C2 was injected at varying concentrations to generate a binding isotherm of resonance units 
bound (saturating response units) versus protein concentrations. The solid lines represent a 
theoretical curve obtained based on Rmax and Kd values determined by nonlinear least 
squares analysis. Representative curves are shown for synthetic-PA (●) and dansyl-PA (○). 
Error bars are indicative of the standard deviation calculated from three separate 
measurements.
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Scheme 1. Synthetic route to protected azide-tagged modular PA scaffold 2
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Scheme 2. Convenient derivatization of protected PA scaffold 2 for the efficient production of 
derivatized PA probes 12a–e
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Scheme 3. Application of modular scaffold 2 for the production of bifunctional PA probe 12f
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Table 1
Dissociation constants measured for binding of PKCα–C2 to vesicles containing PA derivatives.
POPC:POPE:PA (40:40:20) Kd (nM)a
Synthetic PA (POPA) 440 ± 50
Azido PA (1b) 640 ± 140
Naphthyl PA (12a) 780 ± 50
Dansyl PA (12b) 800 ± 70
Coumarin PA (12c) 850 ± 120
Rhodamine PA (12d) 510 ± 90
Benzophenone PA (12e) 570 ± 150
Benzophenone/Azido PA (12f) 520 ± 80
POPC:POPE:PA (55:40:5) Kd (nM)a
Synthetic PA (POPA) 490 ± 90
Azido PA (1b) 730 ± 130
Coumarin PA (12c) 940 ± 120
Rhodamine PA (12d) 810 ± 80
a
Binding experiments were performed in 25 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM CaCl2 and 1 mM DTT
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